CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy. For this purpose we have developed CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit (IC(50) approximately 200 nM), while other tyrosine or serine/threonine kinases were not significantly inhibited. In Ba/F3 cells expressing different FLT3-ITD mutants, CT53518 inhibited IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC(50) of 10-100 nM. In human FLT3-ITD-positive AML cell lines, CT53518 induced apoptosis and inhibited FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways. Therapeutic efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of FLT3-ITD-induced disease.

[1]  Z. Xia,et al.  Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. , 2002, Blood.

[2]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[3]  R. Jove,et al.  The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. , 2000, Cancer research.

[4]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[5]  I. Lemischka,et al.  Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells , 1993, Molecular and cellular biology.

[6]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[7]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[8]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[9]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  Z. Estrov,et al.  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Tomasson,et al.  TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor , 1999 .

[12]  J. Aster,et al.  Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.

[13]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[14]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[15]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[16]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[17]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[18]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[19]  E. Vellenga,et al.  Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts , 2000, Leukemia.

[20]  D. Birnbaum,et al.  The CBL-related Protein CBLB Participates in FLT3 and Interleukin-7 Receptor Signal Transduction in Pro-B Cells* , 1998, The Journal of Biological Chemistry.

[21]  H. Saito,et al.  Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells , 1997, Leukemia.

[22]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[23]  T. Pawson,et al.  Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. , 1994, Oncogene.

[24]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[25]  K. Orita,et al.  Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23) , 1997, Leukemia.

[26]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[27]  D. Birnbaum,et al.  SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor , 1999, Leukemia.

[28]  H. Broxmeyer,et al.  Flt3 signaling involves tyrosyl‐phosphorylation of SHP‐2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells , 1999, Journal of leukocyte biology.

[29]  B. Druker,et al.  STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.

[30]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[31]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[32]  F. McCormick,et al.  Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. , 1997, Science.

[33]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[34]  F. McCormick,et al.  Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. , 1998, Science.

[35]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[36]  B. Löwenberg,et al.  Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene , 2000, Leukemia.

[37]  K. Matsuno,et al.  Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. , 2001, The Journal of pharmacology and experimental therapeutics.

[38]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Reilly,et al.  FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. , 2000 .

[40]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[41]  J. Reilly,et al.  Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia , 2001, British journal of haematology.

[42]  E. Vellenga,et al.  Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. , 2000, Blood.

[43]  H. Saito,et al.  Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation , 1999, Leukemia.

[44]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[45]  D. Gilliland,et al.  Signal transduction and transforming properties of the TEL–TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia , 2000, The EMBO journal.

[46]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[47]  M. Hallek,et al.  The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  D. Small,et al.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.

[49]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.